Details for New Drug Application (NDA): 210203
✉ Email this page to a colleague
The generic ingredient in CAPECITABINE is capecitabine. There are twenty-eight drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the capecitabine profile page.
Summary for 210203
| Tradename: | CAPECITABINE |
| Applicant: | Hetero Labs Ltd V |
| Ingredient: | capecitabine |
| Patents: | 0 |
Pharmacology for NDA: 210203
| Mechanism of Action | Nucleic Acid Synthesis Inhibitors |
Medical Subject Heading (MeSH) Categories for 210203
Suppliers and Packaging for NDA: 210203
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CAPECITABINE | capecitabine | TABLET;ORAL | 210203 | ANDA | Camber Pharmaceuticals, Inc. | 31722-774 | 31722-774-60 | 60 TABLET, FILM COATED in 1 BOTTLE (31722-774-60) |
| CAPECITABINE | capecitabine | TABLET;ORAL | 210203 | ANDA | Camber Pharmaceuticals, Inc. | 31722-775 | 31722-775-12 | 120 TABLET, FILM COATED in 1 BOTTLE (31722-775-12) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 150MG | ||||
| Approval Date: | Mar 5, 2024 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 500MG | ||||
| Approval Date: | Mar 5, 2024 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
